BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Semin Immunopathol 2014;36:399-420. [PMID: 24526222 DOI: 10.1007/s00281-014-0416-x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 67] [Article Influence: 11.5] [Reference Citation Analysis]
Number Citing Articles
1 Conway EM. HUS and the case for complement. Blood. 2015;126:2085-2090. [PMID: 26396094 DOI: 10.1182/blood-2015-03-569277] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
2 Ağbaş A, Göknar N, Akıncı N, Yıldırım ZY, Taşdemir M, Benzer M, Gökçe İ, Candan C, Küçük N, Uzuner S, Özçelik G, Demirkol D, Sever L, Çalışkan S. Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab. Pediatr Nephrol 2018;33:2371-81. [PMID: 30159625 DOI: 10.1007/s00467-018-4033-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
3 Nozal P, Bernabéu-herrero ME, Uzonyi B, Szilágyi Á, Hyvärinen S, Prohászka Z, Jokiranta TS, Sánchez-corral P, López-trascasa M, Józsi M. Heterogeneity but individual constancy of epitopes, isotypes and avidity of factor H autoantibodies in atypical hemolytic uremic syndrome. Molecular Immunology 2016;70:47-55. [DOI: 10.1016/j.molimm.2015.12.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
4 Rivas M, Chinen I, Guth BEC. Enterohemorrhagic (Shiga Toxin-Producing) Escherichia coli. In: Torres AG, editor. Escherichia coli in the Americas. Cham: Springer International Publishing; 2016. pp. 97-123. [DOI: 10.1007/978-3-319-45092-6_5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Sarig G. ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies. Rambam Maimonides Med J 2014;5:e0026. [PMID: 25386342 DOI: 10.5041/RMMJ.10160] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lee JM, Park YS, Lee JH, Park SJ, Shin JI, Park YH, Yoo KH, Cho MH, Kim SY, Kim SH, Namgoong MK, Lee SJ, Lee JH, Cho HY, Han KH, Kang HG, Ha IS, Bae JS, Kim NK, Park WY, Cheong HI. Atypical hemolytic uremic syndrome: Korean pediatric series. Pediatr Int 2015;57:431-8. [PMID: 25443527 DOI: 10.1111/ped.12549] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
7 Feitz WJC, van Setten PA, van der Velden TJAM, Licht C, van den Heuvel LPJW, van de Kar NCAJ. Cell Biological Responses after Shiga Toxin-1 Exposure to Primary Human Glomerular Microvascular Endothelial Cells from Pediatric and Adult Origin. Int J Mol Sci 2021;22:5615. [PMID: 34070679 DOI: 10.3390/ijms22115615] [Reference Citation Analysis]
8 Kallianpur AR, Bradford Y, Mody RK, Garman KN, Comstock N, Lathrop SL, Lyons C, Saupe A, Wymore K, Canter JA, Olson LM, Palmer A, Jones TF. Genetic Susceptibility to Postdiarrheal Hemolytic-Uremic Syndrome After Shiga Toxin-Producing Escherichia coli Infection: A Centers for Disease Control and Prevention FoodNet Study. J Infect Dis 2018;217:1000-10. [PMID: 29216383 DOI: 10.1093/infdis/jix633] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wijnsma KL, Veissi ST, de Wijs S, van der Velden T, Volokhina EB, Wagener FADTG, van de Kar NCAJ, van den Heuvel LP. Heme as Possible Contributing Factor in the Evolvement of Shiga-Toxin Escherichia coli Induced Hemolytic-Uremic Syndrome. Front Immunol 2020;11:547406. [PMID: 33414780 DOI: 10.3389/fimmu.2020.547406] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Wada H, Matsumoto T, Suzuki K, Imai H, Katayama N, Iba T, Matsumoto M. Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thromb J 2018;16:14. [PMID: 30008620 DOI: 10.1186/s12959-018-0168-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 24] [Article Influence: 9.5] [Reference Citation Analysis]
11 Pianciola L, Rivas M. Genotypic Features of Clinical and Bovine Escherichia coli O157 Strains Isolated in Countries with Different Associated-Disease Incidences. Microorganisms 2018;6:E36. [PMID: 29702577 DOI: 10.3390/microorganisms6020036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
12 Danobeitia JS, Djamali A, Fernandez LA. The role of complement in the pathogenesis of renal ischemia-reperfusion injury and fibrosis. Fibrogenesis Tissue Repair 2014;7:16. [PMID: 25383094 DOI: 10.1186/1755-1536-7-16] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 6.8] [Reference Citation Analysis]
13 Kreuzer M, Sollmann L, Ruben S, Leifheit-nestler M, Fischer D, Pape L, Haffner D. Endothelial dysfunction during long-term follow-up in children with STEC hemolytic-uremic syndrome. Pediatr Nephrol 2017;32:1005-11. [DOI: 10.1007/s00467-016-3574-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
14 Hofer J, Rosales A, Fischer C, Giner T. Extra-renal manifestations of complement-mediated thrombotic microangiopathies. Front Pediatr. 2014;2:97. [PMID: 25250305 DOI: 10.3389/fped.2014.00097] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
15 Galarce N, Sánchez F, Fuenzalida V, Ramos R, Escobar B, Lapierre L, Paredes-Osses E, Arriagada G, Alegría-Morán R, Lincopán N, Fuentes-Castillo D, Vera-Leiva A, González-Rocha G, Bello-Toledo H, Borie C. Phenotypic and Genotypic Antimicrobial Resistance in Non-O157 Shiga Toxin-Producing Escherichia coli Isolated From Cattle and Swine in Chile. Front Vet Sci 2020;7:367. [PMID: 32754621 DOI: 10.3389/fvets.2020.00367] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Wijnsma KL, Ter Heine R, Moes DJAR, Langemeijer S, Schols SEM, Volokhina EB, van den Heuvel LP, Wetzels JFM, van de Kar NCAJ, Brüggemann RJ. Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clin Pharmacokinet 2019;58:859-74. [PMID: 30758736 DOI: 10.1007/s40262-019-00742-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 19.0] [Reference Citation Analysis]
17 Saito D, Watanabe E, Ashida A, Kato H, Yoshida Y, Nangaku M, Ohtsuka Y, Miyata T, Hattori N, Oda S. Atypical Hemolytic Uremic Syndrome With the p.Ile1157Thr C3 Mutation Successfully Treated With Plasma Exchange and Eculizumab: A Case Report. Crit Care Explor 2019;1:e0008. [PMID: 32166254 DOI: 10.1097/CCE.0000000000000008] [Reference Citation Analysis]
18 Laužikienė D, Vosylius S, Šiaudinytė I, Laužikas E, Ramašauskaitė D, Bartkevičienė D. Placenta percreta complicated by uterine rupture and thrombotic microangiopathy. Acta Med Litu 2018;25:61-5. [PMID: 30210239 DOI: 10.6001/actamedica.v25i2.3758] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Puentes SS, Dunstan M. Escherichia coli Complications in Pediatric Critical Care. Crit Care Nurs Clin North Am 2018;30:149-56. [PMID: 29413210 DOI: 10.1016/j.cnc.2017.10.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
20 Shah S, Sweis L. A Case Report of Atypical Hemolytic Uremic Syndrome in a Two-Month-Old Infant With a Negative Reported Genetic Profile and Five-Year Follow-Up on Eculizumab. Cureus 2020;12:e10392. [PMID: 32944483 DOI: 10.7759/cureus.10392] [Reference Citation Analysis]
21 Long B, Bridwell RE, Manchanda S, Gottlieb M. Evaluation and Management of Thrombotic Thrombocytopenic Purpura in the Emergency Department. J Emerg Med 2021;61:674-82. [PMID: 34518045 DOI: 10.1016/j.jemermed.2021.07.045] [Reference Citation Analysis]
22 Noris M, Mele C, Remuzzi G. Podocyte dysfunction in atypical haemolytic uraemic syndrome. Nat Rev Nephrol 2015;11:245-52. [PMID: 25599621 DOI: 10.1038/nrneph.2014.250] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
23 Gómez Delgado I, Corvillo F, Nozal P, Arjona E, Madrid Á, Melgosa M, Bravo J, Szilágyi Á, Csuka D, Veszeli N, Prohászka Z, Sánchez-Corral P. Complement Genetic Variants and FH Desialylation in S. pneumoniae-Haemolytic Uraemic Syndrome. Front Immunol 2021;12:641656. [PMID: 33777036 DOI: 10.3389/fimmu.2021.641656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Øzbay LA. Eculizumab treatment of thrombotic microangiopathy in a patient with ulcerative colitis. Clin J Gastroenterol 2020;13:344-8. [PMID: 31612381 DOI: 10.1007/s12328-019-01052-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
25 Omura T, Watanabe E, Otsuka Y, Yoshida Y, Kato H, Nangaku M, Miyata T, Oda S. Complete remission of thrombotic microangiopathy after treatment with eculizumab in a patient with non-Shiga toxin-associated bacterial enteritis: A case report. Medicine (Baltimore) 2016;95:e4104. [PMID: 27399110 DOI: 10.1097/MD.0000000000004104] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Feitz WJC, Suntharalingham S, Khan M, Ortiz-Sandoval CG, Palaniyar N, van den Heuvel LP, van de Kar NCAJ, Licht C. Shiga Toxin 2a Induces NETosis via NOX-Dependent Pathway. Biomedicines 2021;9:1807. [PMID: 34944623 DOI: 10.3390/biomedicines9121807] [Reference Citation Analysis]
27 Páramo JA. [Microvascular thrombosis and clinical implications]. Med Clin (Barc) 2021;156:609-14. [PMID: 33875227 DOI: 10.1016/j.medcli.2020.12.042] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Lazem M, Sheikhtaheri A, Hooman N. Lessons learned from hemolytic uremic syndrome registries: recommendations for implementation. Orphanet J Rare Dis 2021;16:240. [PMID: 34034793 DOI: 10.1186/s13023-021-01871-9] [Reference Citation Analysis]
29 Wijnsma KL, van Bommel SA, van der Velden T, Volokhina E, Schreuder MF, van den Heuvel LP, van de Kar NC. Fecal diagnostics in combination with serology: best test to establish STEC-HUS. Pediatr Nephrol 2016;31:2163-70. [PMID: 27240858 DOI: 10.1007/s00467-016-3420-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
30 Danobeitia JS, Djamali A, Fernandez LA. The role of complement in the pathogenesis of renal ischemia-reperfusion injury and fibrosis. Fibrogenesis Tissue Repair 2014;7:16. [PMID: 25383094 DOI: 10.1186/1755-1536-7-16] [Cited by in Crossref: 57] [Cited by in F6Publishing: 1] [Article Influence: 7.1] [Reference Citation Analysis]
31 Conway EM. Complement-coagulation connections. Blood Coagul Fibrinolysis 2018;29:243-51. [PMID: 29517503 DOI: 10.1097/MBC.0000000000000720] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 5.8] [Reference Citation Analysis]
32 Bokori-Brown M, Metz J, Petrov PG, Mussai F, De Santo C, Smart NJ, Saunders S, Knight B, Pastan I, Titball RW, Winlove CP. Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy. Front Oncol 2018;8:553. [PMID: 30538953 DOI: 10.3389/fonc.2018.00553] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Vaterodt L, Holle J, Hüseman D, Müller D, Thumfart J. Short- and Long-Term Renal Outcome of Hemolytic-Uremic Syndrome in Childhood. Front Pediatr 2018;6:220. [PMID: 30131950 DOI: 10.3389/fped.2018.00220] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
34 Bitzan M, Lapeyraque A. Postinfectious Hemolytic Uremic Syndrome. In: Geary DF, Schaefer F, editors. Pediatric Kidney Disease. Berlin: Springer Berlin Heidelberg; 2016. pp. 653-731. [DOI: 10.1007/978-3-662-52972-0_26] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
35 Volokhina EB, Feitz WJC, Elders LM, van der Velden TJAM, van de Kar NCAJ, van den Heuvel LPWJ. Shiga Toxin Selectively Upregulates Expression of Syndecan-4 and Adhesion Molecule ICAM-1 in Human Glomerular Microvascular Endothelium. Toxins (Basel) 2020;12:E435. [PMID: 32635212 DOI: 10.3390/toxins12070435] [Reference Citation Analysis]
36 Imdad A, Mackoff SP, Urciuoli DM, Syed T, Tanner-Smith EE, Huang D, Gomez-Duarte OG. Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome. Cochrane Database Syst Rev 2021;7:CD012997. [PMID: 34219224 DOI: 10.1002/14651858.CD012997.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Buelli S, Zoja C, Remuzzi G, Morigi M. Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome. Microorganisms 2019;7:E15. [PMID: 30634669 DOI: 10.3390/microorganisms7010015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
38 Contreras E, de la Rubia J, Del Río-Garma J, Díaz-Ricart M, García-Gala JM, Lozano M; Grupo Español de Aféresis. [Diagnostic and therapeutic guidelines of thrombotic microangiopathies of the Spanish Apheresis Group]. Med Clin (Barc) 2015;144:331.e1-331.e13. [PMID: 25433791 DOI: 10.1016/j.medcli.2014.09.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
39 Leinøe E, Nielsen OJ, Jønson L, Rossing M. Whole-exome sequencing of a patient with severe and complex hemostatic abnormalities reveals a possible contributing frameshift mutation in C3AR1. Cold Spring Harb Mol Case Stud 2016;2:a000828. [PMID: 27551680 DOI: 10.1101/mcs.a000828] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
40 Ricklin D, Reis ES, Lambris JD. Complement in disease: a defence system turning offensive. Nat Rev Nephrol. 2016;12:383-401. [PMID: 27211870 DOI: 10.1038/nrneph.2016.70] [Cited by in Crossref: 248] [Cited by in F6Publishing: 246] [Article Influence: 41.3] [Reference Citation Analysis]
41 Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ; EHA Roadmap for European Hematology Research. The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica 2016;101:115-208. [PMID: 26819058 DOI: 10.3324/haematol.2015.136739] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 7.7] [Reference Citation Analysis]
42 Wijnsma KL, Schijvens AM, Rossen JWA, Kooistra-Smid AMDM, Schreuder MF, van de Kar NCAJ. Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2. Pediatr Nephrol 2017;32:1263-8. [PMID: 28343354 DOI: 10.1007/s00467-017-3642-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
43 Ronco P, Floege J. Ten-year advances in immunopathology of glomerulonephritis: translated into patients' care or lost in translation? Semin Immunopathol 2014;36:377-9. [PMID: 25056156 DOI: 10.1007/s00281-014-0437-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
44 Harkins VJ, Mcallister DA, Reynolds BC. Shiga-Toxin E. coli Hemolytic Uremic Syndrome: Review of Management and Long-term Outcome. Curr Pediatr Rep 2020;8:16-25. [DOI: 10.1007/s40124-020-00208-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
45 Liu Y, Tian S, Thaker H, Dong M. Shiga Toxins: An Update on Host Factors and Biomedical Applications. Toxins (Basel) 2021;13:222. [PMID: 33803852 DOI: 10.3390/toxins13030222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
46 Andersen GR. Mutations in complement C3 from aHUS patients. Blood 2015;125:2316-8. [PMID: 25858888 DOI: 10.1182/blood-2015-02-625285] [Reference Citation Analysis]
47 Ekdahl KN, Teramura Y, Hamad OA, Asif S, Duehrkop C, Fromell K, Gustafson E, Hong J, Kozarcanin H, Magnusson PU, Huber-Lang M, Garred P, Nilsson B. Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross-talk act as a linchpin in the events leading to thromboinflammation. Immunol Rev 2016;274:245-69. [PMID: 27782319 DOI: 10.1111/imr.12471] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 14.2] [Reference Citation Analysis]
48 Kuppachi S, Smith RJH, Thomas CP. Evaluation of Genetic Renal Diseases in Potential Living Kidney Donors. Curr Transpl Rep 2015;2:1-14. [DOI: 10.1007/s40472-014-0042-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
49 Park JY, Jeong YJ, Park SK, Yoon SJ, Choi S, Jeong DG, Chung SW, Lee BJ, Kim JH, Tesh VL, Lee MS, Park YJ. Shiga Toxins Induce Apoptosis and ER Stress in Human Retinal Pigment Epithelial Cells. Toxins (Basel) 2017;9:E319. [PMID: 29027919 DOI: 10.3390/toxins9100319] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
50 Wadehra A, Alkassis S. Atypical Hemolytic Uremic Syndrome in the Setting of Acute Clostridium difficile Colitis. Cureus 2021;13:e13244. [PMID: 33728192 DOI: 10.7759/cureus.13244] [Reference Citation Analysis]
51 Karpman D, Loos S, Tati R, Arvidsson I. Haemolytic uraemic syndrome. J Intern Med 2017;281:123-48. [DOI: 10.1111/joim.12546] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
52 Schwarz C, Brehon A, Mousseaux C, Luque Y, Senet P, Mariani P, Mohamadou I, Zafrani L, Frémeaux-Bacchi V, Rondeau E, Buob D, Rafat C. Ockham's razor defeated: about two atypical cases of hemolytic uremic syndrome. BMC Nephrol 2020;21:269. [PMID: 32652955 DOI: 10.1186/s12882-020-01926-2] [Reference Citation Analysis]
53 Durey MA, Sinha A, Togarsimalemath SK, Bagga A. Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol 2016;12:563-78. [PMID: 27452363 DOI: 10.1038/nrneph.2016.99] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
54 Jokiranta TS. HUS and atypical HUS. Blood. 2017;129:2847-2856. [PMID: 28416508 DOI: 10.1182/blood-2016-11-709865] [Cited by in Crossref: 124] [Cited by in F6Publishing: 101] [Article Influence: 24.8] [Reference Citation Analysis]
55 Krüger A, Lucchesi PMA. Shiga toxins and stx phages: highly diverse entities. Microbiology 2015;161:451-62. [DOI: 10.1099/mic.0.000003] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 11.3] [Reference Citation Analysis]
56 Jinnerot T, Tomaselli ATP, Johannessen GS, Söderlund R, Urdahl AM, Aspán A, Sekse C. The prevalence and genomic context of Shiga toxin 2a genes in E. coli found in cattle. PLoS One 2020;15:e0232305. [PMID: 32785271 DOI: 10.1371/journal.pone.0232305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Emmi G, Silvestri E, Squatrito D, Ciucciarelli L, Cameli AM, Denas G, D'Elios MM, Pengo V, Emmi L, Prisco D. An approach to differential diagnosis of antiphospholipid antibody syndrome and related conditions. ScientificWorldJournal 2014;2014:341342. [PMID: 25374937 DOI: 10.1155/2014/341342] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
58 Watson R, Wearmouth E, McLoughlin AC, Jackson A, Ward S, Bertram P, Bennaceur K, Barker CE, Pappworth IY, Kavanagh D, Lea SM, Atkinson JP, Goodship TH, Marchbank KJ. Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 2015;63:287-96. [PMID: 25150608 DOI: 10.1016/j.molimm.2014.07.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
59 Lee H, Kang E, Kang HG, Kim YH, Kim JS, Kim HJ, Moon KC, Ban TH, Oh SW, Jo SK, Cho H, Choi BS, Hong J, Cheong HI, Oh D. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020;35:25-40. [PMID: 31935318 DOI: 10.3904/kjim.2019.388] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
60 Galarce N, Escobar B, Sánchez F, Paredes-Osses E, Alegría-Morán R, Borie C. Virulence Genes, Shiga Toxin Subtypes, Serogroups, and Clonal Relationship of Shiga Toxin-Producing Escherichia Coli Strains Isolated from Livestock and Companion Animals. Animals (Basel) 2019;9:E733. [PMID: 31569618 DOI: 10.3390/ani9100733] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
61 Zhai YL, Meng SJ, Zhu L, Shi SF, Wang SX, Liu LJ, Lv JC, Yu F, Zhao MH, Zhang H. Rare Variants in the Complement Factor H-Related Protein 5 Gene Contribute to Genetic Susceptibility to IgA Nephropathy. J Am Soc Nephrol 2016;27:2894-905. [PMID: 26825529 DOI: 10.1681/ASN.2015010012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
62 Santangelo L, Netti GS, Torres DD, Piscopo G, Carbone V, Losito L, Milella L, Lasorella ML, Conti P, Gagliardi D, Chironna M, Spadaccino F, Bresin E, Trabacca A, Ranieri E, Giordano M. Peripheral nervous system manifestations of Shiga toxin-producing E. coli-induced haemolytic uremic syndrome in children. Ital J Pediatr 2021;47:181. [PMID: 34488831 DOI: 10.1186/s13052-021-01133-1] [Reference Citation Analysis]
63 Jiang H, Fan MN, Yang M, Lu C, Zhang M, Liu XH, Ma L. Association among Complement Factor H Autoantibodies, Deletions of CFHR, and the Risk of Atypical Hemolytic Uremic Syndrome. Int J Environ Res Public Health 2016;13:E1209. [PMID: 27929404 DOI: 10.3390/ijerph13121209] [Cited by in Crossref: 6] [Article Influence: 1.0] [Reference Citation Analysis]
64 Vaisbich MH, Braga A, Gabrielle M, Bueno C, Piazzon F, Kok F. Thrombotic microangiopathy caused by methionine synthase deficiency: diagnosis and treatment pitfalls. Pediatr Nephrol 2017;32:1089-92. [PMID: 28210839 DOI: 10.1007/s00467-017-3615-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
65 Lee MS, Koo S, Jeong DG, Tesh VL. Shiga Toxins as Multi-Functional Proteins: Induction of Host Cellular Stress Responses, Role in Pathogenesis and Therapeutic Applications. Toxins (Basel) 2016;8:E77. [PMID: 26999205 DOI: 10.3390/toxins8030077] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 8.8] [Reference Citation Analysis]
66 Conway EM. Reincarnation of ancient links between coagulation and complement. J Thromb Haemost 2015;13 Suppl 1:S121-32. [PMID: 26149013 DOI: 10.1111/jth.12950] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 10.0] [Reference Citation Analysis]
67 Lafalla Manzano AF, Gil Lorenzo AF, Bocanegra V, Costantino VV, Cacciamani V, Benardon ME, Vallés PG. Rab7b participation on the TLR4 (Toll-like receptor) endocytic pathway in Shiga toxin-associated Hemolytic Uremic Syndrome (HUS). Cytokine 2019;121:154732. [PMID: 31153054 DOI: 10.1016/j.cyto.2019.05.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Azoulay E, Knoebl P, Garnacho-Montero J, Rusinova K, Galstian G, Eggimann P, Abroug F, Benoit D, von Bergwelt-Baildon M, Wendon J, Scully M. Expert Statements on the Standard of Care in Critically Ill Adult Patients With Atypical Hemolytic Uremic Syndrome. Chest 2017;152:424-34. [PMID: 28442312 DOI: 10.1016/j.chest.2017.03.055] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
69 da Cruz Gouveia MA, Lins MTC, da Silva GAP. Acute diarrhea with blood: diagnosis and drug treatment. J Pediatr (Rio J) 2020;96 Suppl 1:20-8. [PMID: 31604059 DOI: 10.1016/j.jped.2019.08.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
70 Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, Hidaka Y, Kaname S, Maruyama S, Yasuda T, Yoshida Y, Ito S, Hattori M, Miyakawa Y, Fujimura Y, Okada H, Kagami S; Joint Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan. Clinical guides for atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol 2016;20:536-43. [PMID: 27422619 DOI: 10.1007/s10157-016-1276-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
71 Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, Hidaka Y, Kaname S, Maruyama S, Yasuda T, Yoshida Y, Ito S, Hattori M, Miyakawa Y, Fujimura Y, Okada H, Kagami S; Joint Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan. Clinical guides for atypical hemolytic uremic syndrome in Japan. Pediatr Int. 2016;58:549-555. [PMID: 27460397 DOI: 10.1111/ped.13044] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
72 Mele C, Lemaire M, Iatropoulos P, Piras R, Bresin E, Bettoni S, Bick D, Helbling D, Veith R, Valoti E, Donadelli R, Murer L, Neunhäuserer M, Breno M, Frémeaux-Bacchi V, Lifton R, Remuzzi G, Noris M. Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome. Clin J Am Soc Nephrol 2015;10:1011-9. [PMID: 25854283 DOI: 10.2215/CJN.08520814] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]